Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development
Open Access
- 1 March 2015
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 6 (3), 120-127
- https://doi.org/10.1177/2040620715572295
Abstract
Despite the recent major advancement in therapy for multiple myeloma, it remains an incurable disease. There remains an unmet need for novel therapies that target different mechanisms of action. Immunotherapy with monoclonal antibodies is a promising area of development and will expand our therapeutic armamentarium in the fight against myeloma. Daratumumab is a novel, high-affinity, therapeutic human monoclonal antibody against unique CD38 epitope with broad-spectrum killing activity. It has a favorable safety profile as monotherapy in patients with relapsed/refractory myeloma and also demonstrates significant single-agent activity. Abundant preclinical data supports its use in combination therapy and clinical studies on various exciting combinations are underway. This review focuses on the CD38 antigen and its targeting with daratumumab and provides an update on the results of recent clinical studies involving daratumumab.Keywords
This publication has 29 references indexed in Scilit:
- Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term SurvivalJournal of Clinical Oncology, 2012
- Emergence of central nervous system myeloma in the era of novel agentsHematological Oncology, 2011
- The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapiesBlood Cancer Journal, 2011
- CD38 and chronic lymphocytic leukemia: a decade laterBlood, 2011
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabHaematologica, 2010
- Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBlood, 2010
- CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf–mediated interactions with bone marrow stromal cellsPublished by American Society of Hematology ,2009
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Molecular modeling of the GABAC receptor ligand-binding domainJournal of Molecular Modeling, 2005
- A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1British Journal of Haematology, 1996